

# Financial Tear Sheet

## Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

## Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$4.30
Change (%)	▼ 0.11 (2.49%)
Volume	62,021
52 Week Low	\$2.88
Market Cap	\$84,280,948
Rolling EPS	-0.29
PE Ratio	0
Shares Outstanding	19,111,326
Data as of 06/18/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

June 7, 2018

**BRAINSTORM ANNOUNCES EXERCISE OF WARRANTS RESULTING IN CASH PROCEEDS OF ~\$12.3 MILLION AT \$5 SHARE**

June 1, 2018

**BRAINSTORM TO HOST CALL FOLLOWING PRESIDENT TRUMP'S CITING OF COMPANY'S ALS TREATMENT DURING "RIGHT-TO-TRY" BILL SIGNING**

May 30, 2018

**BRAINSTORM CELL THERAPEUTICS TO PROVIDE CORPORATE UPDATE AT THE BIO INTERNATIONAL CONVENTION**

## SEC Filings

Filing Date	Form
06/08/18	S-3
06/07/18	424B3
06/07/18	8-K
05/14/18	10-Q

## Upcoming Events

**BRAINSTORM CELL THERAPEUTICS - FIRST QUARTER 2018 EARNINGS CALL**

May 14, 2018 8:30 a.m. ET

**WALL STREET INVESTOR FORUM COMPANY PRESENTATION**

March 22, 2018 8:00 a.m. ET

## Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)